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Summary
Background: The effect of early statin initiation on secondary prevention remains uncertain in
unselected Japanese populations with coronary artery disease (CAD).
Methods: We investigated the mortality and morbidity in CAD patients according to presence
or absence of statins within 3 months after the diagnosis of CAD in the Shinken Database cohort
study. The primary endpoint was all-cause mortality.
Results: Data were available on 789 Japanese patients with CAD (male 78.8%). Among those,
351 patients (44.5%) received a statin. The mean (SD) baseline low-density lipoprotein (LDL)-
cholesterol levels were 113.6 (35.7) mg/dL in the statin group and 113.6 (26.4) mg/dL in the
non-statin group (p = 0.992). Unadjusted 2-year survival in patients with or without statins was
98.4% and 92.1%, respectively (p < 0.001). Among a prespeciﬁed subgroup of patients undergoing
percutaneous coronary intervention (PCI) (n = 238 with statins and n = 183 without statins), a
consistent effect of statins on 2-year survival was observed (98.5% and 90.9%, respectively,
p < 0.001). However, there was no signiﬁcant difference in 2-year target lesion revascularization-
free survival (77.9% in statins versus 73.7% in non-statins, respectively, p = 0.298). The age- and
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gender-adjusted survival in the PCI subgroup was signiﬁcantly higher in the statin group [hazard
ratio (HR) 0.29, 95% conﬁdence interval (CI) 0.095—0.913] compared to non-statin. Multivariate
analysis showed statins signiﬁcantly reduced mortality (HR 0.27, 95%CI 0.078—0.944), but not
revascularization (HR 0.91, 95%CI 0.589—1.406).
Conclusions: This study suggested that statin therapy initiated early after the diagnosis of CAD
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an estimated glomerular ﬁltration rate (GFR), calcu-
lated by using the GFR equation for Japanese subjects;can decrease the risk of fata
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Introduction
Coronary artery disease (CAD) is one of the three major
causes of death in Asia and its prevalence is increasing as the
mean age of the population increases and lifestyle changes
[1]. Current treatment modalities for the treatment of
CAD include lifestyle changes, medication, coronary artery
bypass grafting (CABG), and percutaneous coronary inter-
vention (PCI). With regard to medication, statins have been
shown in large-scale randomized clinical trials to reduce car-
diovascular morbidity and mortality from CAD as primary
[2—4] and secondary prevention [5—12]. In terms of statin
dose, intensive statin treatment seems to be more effective
than standard-dose statins after acute coronary syndrome
(ACS) [11,13,14] and in patients with stable angina pectoris
[15,16]. However, standard doses of statins used in pre-
vious studies conducted in Western countries were larger
than standard doses approved in Japan. Asian people are
thought to be more responsive to therapeutic drugs than
Caucasians and standard doses seem to provide the same
beneﬁt to Asian patients as those observed with higher doses
in Caucasians [17].
On the other hand, the timing of statin initiation after the
diagnosis of CAD also seems to be important for the prog-
nosis. Several studies [8,18—20] but not all [21,22] showed
that early statin initiation after ACS is related to a reduction
in mortality and recurrent cardiovascular events. Previous
studies conducted so far showed mixed results. In stable
CAD, the effect of statins on coronary atheromatous plaque
reduction was demonstrated by the assessment of intravas-
cular ultrasound [23]. This study was conducted in Japanese
patients by using rosuvastatin of approved dose in Japan.
Therefore, we hypothesized that early statin initiation
after the diagnosis of CAD decreases mortality and recur-
rent cardiovascular events in the Japanese CAD population
regardless of CAD types in real-world clinical settings,
although there have been few cohort studies conducted in
Japan to examine the effect of early statin initiation. To
test the hypothesis, we assessed the prognosis according to
presence or absence of statins within 3 months after the
diagnosis of CAD by using the observational cohort study,
the Shinken Database.
Methods
The Shinken Database and study populationThe Shinken Database is an ongoing hospital-based epidemi-
ological study designed to assess mortality and morbidity
of Japanese patients with cardiovascular diseases and risk
factors [24—26]. The database study population comprised
all new patients who had visited our hospital in Tokyo since
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Ants in Japanese CAD patients.
ology. Published by Elsevier Ltd. All rights reserved.
une 2004 and did not meet the exclusion criteria: patients
ith cancer, patients living abroad, and patients visiting on
single occasion without any examinations. The present
tudy was based on the database between June 2004 and
arch 2007 (n = 6562). Among the subjects included in the
atabase, 822 patients were diagnosed with CAD; the infor-
ation on medication was not obtained in 28 patients and 5
atients with ACS died during hospitalization before taking
edications and were excluded to avoid bias. Therefore, the
emaining 789 patients were included in the present study.
he study population was classiﬁed into 2 groups accord-
ng to presence or absence of statins within 3 months after
he diagnosis of CAD. Of this study population, 351 patients
44.5%) received statin treatment; in a pre-speciﬁed sub-
roup undergoing PCI (421 patients) as a ﬁrst-line treatment
or CAD, 238 patients (56.5%) received statin treatment.
ritten informed consent for inclusion into the Shinken
atabase was obtained from all patients. The data were
ransmitted to the Shinken Database center at the hospi-
al, and all clinical outcomes were monitored by medical
ecords, mail and/or telephone contact with the patients.
he Ethics Committee in the institute granted permission for
his study.
eﬁnitions
n all analyses, statin treatment was deﬁned as statins ini-
iated before the initial arrival or during the ﬁrst 3 months,
nd no statin treatment was deﬁned as no statins prescribed
or the ﬁrst 3 months after the initial visit. The statin ini-
iation was decided by attending physicians. The statins
pproved in Japan during the study period were as follows:
ravastatin, simvastatin, ﬂuvastatin, atorvastatin, pitavas-
atin, and rosuvastatin.
CAD encompasses stable angina pectoris including
ilent myocardial ischemia, unstable angina, non-ST-
egment elevation myocardial infarction, ST-segment
levation myocardial infarction, and coronary spastic
ngina. ACS included unstable angina, non-ST-segment
levation myocardial infarction, and ST-segment eleva-
ion myocardial infarction. Diagnoses were conﬁrmed by
oronary angiogram including fractional ﬂow reserve,
on-invasive tests (stress myocardial scintigraphy, tread-
ill, and stress echocardiography), and/or 24-h holter-
lectrocardiogram. Renal function was determined byFR = 194× (serum creatinine)−1.094 × (age)−0.287 × (0.739 if
emale). Blood sampling for baseline lipid proﬁle was after
10—12 h fast, although some patients, especially with
CS, blood sampling was performed during the acute phase.
ngiographically signiﬁcant stenosis was deﬁned as 50% or
174 M. Nakamura et al.
Table 1 Baseline characteristics (in all patients with coronary artery disease).
Statins p-value
(+) (−)
n = 351 n = 438
Male gender, n (%) 276 (78.6) 346 (79.0) 0.930
Age, years 63.2± 10.7 65.7± 11.9 0.002
Body mass index, kg/m2 24.4± 3.1 23.7± 3.5 0.003
Estimated GFR, ml/min/1.73m2 69.7± 19.9 67.0± 23.9 0.099
Number of diseased coronary arteries, n 1.9± 0.9 1.6± 1.1 < 0.001
History of coronary artery disease
Prior myocardial infarction, n (%) 111 (31.6) 101 (23.1) 0.008
Prior CABG, n (%) 17 (4.8) 27 (6.2) 0.440
Prior PCI, n (%) 90 (25.6) 49 (11.2) <0.001
Presentation on the initial arrival
Stable angina, n (%) 188 (55.6) 218 (61.9)
0.104Acute coronary syndrome, n (%) 150 (44.4) 134 (38.1)
Comorbidity
Hypertension, n (%) 216 (61.5) 239 (54.6) 0.051
Hyperuricemia, n (%) 53 (15.1) 54 (12.3) 0.295
Diabetes mellitus, n (%) 133 (38.0) 116 (26.5) 0.001
Cigarette smoker, n (%) 211 (60.3) 241 (55.0) 0.147
Lipid values
LDL-cholesterol, mg/dL 113.6± 35.7 113.6± 26.4 0.992
HDL-cholesterol, mg/dL 48.8± 13.0 51.8± 15.7 0.006
Total-cholesterol, mg/dL 199.2± 42.4 193.5± 32.5 0.039
Triglycerides, mg/dL 154.9± 89.7 132.2± 95.6 0.001
Congestive heart failure on arrival, n (%) 43 (12.3) 56 (12.8) 0.830
GFR, glomerular ﬁltration rate; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; LDL, low-density lipopro-
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as mean± standard deviation.
ore stenosis of a major epicardial coronary artery. Angio-
raphic ﬁndings were checked by more than 3 coronary
nterventional cardiologists. Target lesion revascularization
TLR) was deﬁned as PCI for a treated lesion during the index
rocedure or CABG after the index procedure and the indica-
ion for TLR was in case patients had apparent myocardial
schemia by the non-invasive assessment or invasive mea-
urements of fractional ﬂow reserve.
Information on baseline characteristics of patients and
heir cardiac history, risk factors, the ﬁrst therapeutic
trategies (PCI, CABG, or medical without invasive treat-
ents) for CAD and medications at baseline was obtained
n all patients.
tudy end points
he primary end point was death from any cause. The sec-
ndary end point was TLR and cardiovascular events (cardiac
eath, nonfatal myocardial infarction, or readmission for
eart failure). TLR was assessed among only patients under-
oing PCI.tatistical analysis
ontinuous variables between groups were compared using
npaired t-test. Categorical variables were compared using
B
T
i
Msquare for categorical variables. Continuous values are expressed
hi-square test. Results for continuous data were expressed
s mean± standard deviation (SD). Data on patients who
ere lost to follow-up were censored. Cumulative event
urves were plotted by the Kaplan—Meier method stratiﬁed
ccording to presence or absence of statin, and the differ-
nce was tested by log-rank test. The association between
he baseline characteristics and the outcomes was assessed
sing multivariable Cox proportional hazards models. Ten
ovariates of clinical relevance thought to impact the out-
omes were incorporated into the models: presentation
presence or absence of ACS), age, gender, presence or
bsence of diabetes mellitus, the estimated GFR, number
f diseased coronary arteries, congestive heart failure on
dmission, beta-blocker use, use of drug-eluting stent, and
tatin use. Analyses of data were performed using statistical
oftware (SPSS version 14.0; SPSS Japan Inc., Tokyo, Japan).
ll p-values were 2-sided, and signiﬁcance was deﬁned as
< 0.05 for all analyses.
esultsaseline characteristics in all patients with CAD
able 1 shows baseline characteristics at the initial vis-
ts according to the presence or absence of statins.
edian follow-up period was 23.3 months (interquar-
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Table 2 Therapy (in all patients with coronary artery disease).
Statins p-value
(+) (−)
n = 351 n = 438
Therapeutic strategies as a ﬁrst-line treatment
PCI, n (%) 238 (67.8) 183 (41.8) <0.001
Use of stents, n (%) 221 (63.0) 161 (36.8) <0.001
Use of drug-eluting stents, n (%) 130 (37.1) 85 (19.4) <0.001
CABG, n (%) 35 (10.0) 54 (12.3) 0.310
Medical without invasive treatments, n (%) 78 (22.2) 200 (45.7) <0.001
Medications
Angiotensin-converting enzyme inhibitor, n (%) 72 (20.5) 45 (10.3) <0.001
Angiotensin receptor blocker, n (%) 123 (35.0) 106 (24.2) 0.001
Beta-blocker, n (%) 160 (45.6) 124 (28.3) <0.001
Ca channel blocker, n (%) 133 (37.9) 222 (50.7) <0.001
Aspirin, n (%) 335 (95.4) 332 (75.8) <0.001
Cilostazol, n (%) 14 (4.0) 15 (3.4) 0.707
Ticlopidine, n (%) 241 (68.7) 177 (40.4) <0.001
Nicorandil, n (%) 130 (37.0) 139 (31.7) 0.131
Nitrate, n (%) 79 (22.5) 117 (26.7) 0.185
Diuretics, n (%) 75 (21.4) 85 (19.4) 0.533
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DPCI, percutaneous coronary intervention; CABG, coronary artery b
tile range 15.5—33.6 months). Patients with statins were
younger compared to those without statins (63.2± 10.7
years versus 65.7± 11.9 years). Body mass index and num-
ber of diseased coronary arteries were signiﬁcantly higher
among patients receiving statins. Patients with statins
more often had prior myocardial infarction and prior PCI.
There were no signiﬁcant differences in renal function
and the proportion of male gender and presentation (sta-
ble angina or ACS) at the initial visits among the 2
groups. Statins were more often prescribed to patients
with hypertension or diabetes. Patients taking statins
had signiﬁcantly lower high-density lipoprotein (HDL)-
cholesterol level, higher total cholesterol level, and higher
triglycerides level at the initial visits (48.8± 13.0 versus
51.8± 15.7mg/dL, 199.2± 42.4 versus 193.5± 32.5mg/dL,
and 154.9± 89.7 versus 132.2± 95.6mg/dL, respectively).
However, there was no signiﬁcant difference in low-
density lipoprotein (LDL)-cholesterol level (113.6± 35.7
versus 113.6± 26.4mg/dL). Also, the proportion of conges-
tive heart failure at baseline was similar between patients
with statins and without statins (12.3% versus 12.8%, respec-
tively).
Therapeutic strategy and medications in all
patients with CAD
As shown in Table 2, therapeutic strategies and medications
were not well balanced between the 2 groups. Accordingly,
study patients were further split in pre-speciﬁed groups of
patients undergoing PCI as a ﬁrst-line treatment for CAD
or assigned to medical therapy alone or CABG. A total of
421 patients underwent PCI and among them 238 patients
(56.5%) received statins.
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ts graft. Chi-square for categorical variables.
aseline characteristics in the subgroup of patients
ndergoing PCI
able 3 shows the baseline characteristics among patients
ith PCI. The ﬁndings were similar to those in Table 1, but
n this population the estimated GFR value was signiﬁcantly
igher in patients with statins (70.8± 17.6ml/min/1.73m2
ersus 66.0± 24.3ml/min/1.73m2, p = 0.020). The num-
er of diseased coronary arteries was similar among the
groups. There were no apparent differences in the
roportion of patients with comorbidity and congestive
eart failure on arrival, LDL-cholesterol value, and HDL-
holesterol value between the 2 groups. However, total
holesterol value and triglycerides value was signiﬁcantly
igher in patients with statins compared to patients without
tatins.
herapeutic strategies and medications in the
ubgroup of undergoing PCI
able 4 shows the therapeutic strategy for CAD and medica-
ions. There were no signiﬁcant differences in the procedure
f PCI and medications, with the exception of beta-blocker,
hich was more frequently received by patients with statins.
linical outcomes
uring the median follow-up period of 23.3 months, death
rom any causes and cardiovascular events occurred in 7
nd 9 patients, respectively in the statin group, and in
0 and 26 patients, respectively in the non-statin group.
nadjusted 2-year survival rates in the statin group and
he non-statin group were 98.4% and 92.1%, respectively
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Table 3 Baseline characteristics (in the PCI subgroup).
Statins p-value
(+) (−)
n = 238 n = 183
Male gender, n (%) 191 (80.3) 147 (80.3) 1.000
Age, years 64.0± 10.2 67.6± 11.1 0.001
Body mass index, kg/m2 24.6± 3.0 23.7± 3.2 0.003
Estimated GFR, ml/min/1.73m2 70.8± 17.6 66.0± 24.3 0.020
Number of diseased coronary arteries, n 1.9± 0.8 1.9± 0.8 0.561
History of coronary artery disease
Prior myocardial infarction, n (%) 52 (21.8) 32 (17.5) 0.325
Prior CABG, n (%) 5 (2.1) 4 (2.2) 1.000
Prior PCI, n (%) 35 (14.7) 14 (7.7) 0.031
Presentation on the initial arrival
Stable angina, n (%) 108 (45.4) 91 (49.7)
0.378Acute coronary syndrome, n (%) 130 (54.6) 92 (50.3)
Comorbidity
Hypertension, n (%) 149 (62.6) 121 (66.1) 0.474
Hyperuricemia, n (%) 36 (15.1) 21 (11.5) 0.316
Diabetes mellitus, n (%) 93 (39.2) 58 (31.7) 0.124
Cigarette smoker, n (%) 145 (60.9) 96 (52.5) 0.091
Lipid values
LDL-cholesterol, mg/dL 118.5± 36.7 113.9± 26.4 0.166
HDL-cholesterol, mg/dL 48.7± 12.4 49.7± 13.8 0.455
Total-cholesterol, mg/dL 207.0± 42.4 190.4± 31.3 <0.001
Triglycerides, mg/dL 157.2± 91.2 126.0± 109.5 0.002
Congestive heart failure on arrival, n (%) 27 (11.3) 28 (15.3) 0.246
GFR, glomerular ﬁltration rate; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; LDL, low-density lipopro-
tein; HDL, high-density lipoprotein. t-test for continuous variables; chi-square for categorical variables. Continuous values are expressed
as mean± standard deviation.
Table 4 Therapy (in the PCI subgroup).
Statins p-value
(+) (−)
n = 238 n = 183
Procedure of PCI
Stents, n (%) 215 (90.3) 155 (84.7) 0.097
Drug-eluting stents, n (%) 124 (52.1) 82 (44.8) 0.142
DCA, n (%) 19 (8.0) 16 (8.7) 0.859
PTCRA, n (%) 15 (6.3) 19 (10.4) 0.150
Use of intravascular ultrasound 222 (93.3) 166 (90.7) 0.364
Medications
Angiotensin-converting enzyme inhibitor, n (%) 54 (22.7) 30 (16.4) 0.112
Angiotensin receptor blocker, n (%) 82 (34.5) 53 (29.0) 0.248
Beta-blocker, n (%) 115 (48.3) 58 (31.7) 0.001
Ca channel blocker, n (%) 95 (39.9) 90 (49.2) 0.061
Aspirin, n (%) 235 (98.7) 178 (97.3) 0.302
Cilostazol, n (%) 9 (3.8) 10 (5.5) 0.480
Ticlopidine, n (%) 209 (87.8) 150 (82.0) 0.098
Nicorandil, n (%) 87 (36.6) 63 (34.4) 0.682
Nitrate, n (%) 49 (20.6) 35 (19.1) 0.806
Diuretics, n (%) 33 (13.9) 29 (15.8) 0.582
PCI, percutaneous coronary intervention; DCA, directional coronary atherectomy; PTCRA, percutaneous transluminal coronary rotational
ablation. Chi-square for categorical variables.
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tFigure 1 Kaplan—Meier survival curves in patients with coro
percutaneous coronary intervention (B). There were signiﬁcant
(p < 0.001), with corresponding rates of 97.8% and 93.9%
(p = 0.018) for freedom from cardiovascular events (Fig. 1).
Multivariate Cox proportional analysis showed that statin
use was independently associated with lower mortality
from any causes (hazard ratio [HR] 0.27, 95% conﬁdence
interval [CI] 0.097—0.777, p = 0.015), but not with cardio-
vascular events (HR 0.78, 95%CI 0.319—1.900, p = 0.583)
(Table 5).
In the subgroup undergoing PCI (n = 421), 49 patients
with statins and 34 patients without statins underwent TLR.
Unadjusted 2-year survival rates in this population were
98.5% in patients with statins and 90.9% in patients without
statins (p < 0.001), with corresponding rates of 98.2% and
93.8% (p = 0.028) for freedom from cardiovascular events
(Fig. 1). However, there was no signiﬁcant difference in
2-year TLR-free survival (77.9% in statins versus 73.7% in
non-statins, respectively, p = 0.298). The age-and gender-
adjusted survival in the PCI subgroup was signiﬁcantly higher
in the statin group (HR 0.29, 95%CI 0.095—0.913, p = 0.034)
compared to non-statin group. Even after adjustment for
confounding covariates, statin treatment was indepen-
dently associated with lower mortality (HR 0.27, 95%CI
0.078—0.944, p = 0.040), but not with the composite events
of TLR or death (HR 0.91, 95%CI 0.589—1.406, p = 0.671)
l
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Table 5 Clinical outcomes.
Outcomes Ha
All patients with coronary artery disease
Death from any causes 0.
Cardiovascular events 0.
A prespeciﬁed subgroup undergoing PCI
Death from any causes 0.
Cardiovascular events 0.
Composite of death or TLR 0.
Hazard ratio in patients with statins compared to those without stati
nonfatal-myocardial infarction, or readmission for heart failure. PCI, pe
ization; CI, conﬁdence interval.artery disease (A) and in the subgroup of patients undergoing
rences in survival among patients with or without statins.
nd cardiovascular events (HR 0.90, 95%CI 0.257—3.161,
= 0.871) (Table 5).
iscussion
he present study comprises an observational cohort of
nselected patients with CAD and revealed that the early
nitiation of statins used in real-world clinical settings in
apan was associated with a statistically signiﬁcant reduc-
ion in mortality. These ﬁndings also persisted in the PCI
ubgroup, yet the statins did not signiﬁcantly reduce TLR
nd cardiovascular events after PCI. Although to date there
as been limited information showing the impact of early
tatin initiation for unselected Japanese patients with CAD,
ith a broad range of lipid levels, the present study gives
ew importance to early statin initiation by demonstrat-
ng a signiﬁcant reduction in mortality regardless of CAD
ypes. Given the relatively ‘‘low’’ LDL-cholesterol at base-
ine, many patients may not be considered for treatment and
he present study reinforces the concept that CAD patients
hould be on a statin early after the diagnosis.
In the present study, patients receiving statins were
eavier, had more severe CAD, more diabetes and more
zard ratio (95%CI) p-value
27 (0.097—0.777) 0.015
78 (0.319—1.900) 0.583
27 (0.078—0.944) 0.040
90 (0.257—3.161) 0.871
91 (0.589—1.406) 0.671
ns. The cardiovascular events were composed of cardiac death,
rcutaneous coronary intervention; TLR, target lesion revascular-
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yslipidemia at baseline; these imbalances should bias the
esults toward a null effect of treatment. Nevertheless,
tatin treatment signiﬁcantly reduced the mortality rate
n CAD patients. There were also noteworthy differences
n therapeutic strategies between Western countries and
he present study, especially in the proportion of invasive
reatment during hospitalization. We should note that it
s possible that these differences in therapeutic strategies
ight inﬂuence the present ﬁndings about prognosis.
Previous studies conducted in Western countries had
ixed results about early statin initiation for prognosis,
lthough the result of this cohort study was consistent with
hat of the randomized controlled study conducted in Japan
20]. In the present study, the survival curves separated in
he early phase and remained parallel or separated more for
he follow-up period, which is consistent with previous stud-
es [27,28] and conﬁrms the durable beneﬁt of early statin
nitiation. Notable ﬁndings of the present study included the
bservation that the statin treatment initiated early after
he diagnosis of CAD achieved a 73% risk reduction in mor-
ality, suggesting that early statin initiation for Japanese can
rovide a marked beneﬁt in this population in a real world
etting.
We do not fully understand why the statin treatment
nitiated early after diagnosis reduced the mortality rate
n patients with stable angina, ACS, and coronary spastic
ngina. Statins improve acutely endothelial function [29],
ecrease platelet activity [30] and thrombus deposition, and
educe inﬂammation [31,32], which might contribute to a
ecreased mortality rate in not only ACS but stable angina
nd coronary spastic angina.
There was a discrepancy between mortality and cardio-
ascular events in the present study. Prior studies showed
reduction in revascularization rate and other cardiovas-
ular events with statin treatment [5—7,10,11,19,20], but
ere not consistent with the present study. Reduced revas-
ularization rates or lower risk of myocardial infarction with
tatin has been attributed to the stabilization of vulnera-
le plaques, although in the present study even among ACS
atients the 2-year TLR-free survival rates did not reach sta-
istical signiﬁcance (75.1% in the statin group versus 67.8%
n the non-statin group, respectively, p = 0.201). There are
everal possible explanations for this discrepancy. First,
tatins may have a dose-dependent effect on plaque regres-
ion [33]. In addition, baseline LDL-cholesterol levels may
lter the overall beneﬁt of statins [6,34]. In the present
tudy, lipid levels were almost within normal range and it
s possible that statins, used in doses approved for Japanese
ubjects, did not reduce the restenosis rate or atheroscle-
osis burden during the period of follow-up.
Second, statins inhibit activation of platelets and reduce
latelet thrombus formation [30]. The current combina-
ion therapy of aspirin and thienopyridine agents after PCI
educed stent thrombosis [35], which we did not observe
uring the study period. Furthermore, PCI was performed
y a careful technique in stent deployment with frequent
se of intravascular ultrasound (approximately 90%). In addi-
ion, we performed routine follow-up angiography and if
yocardial ischemia was conﬁrmed by stress test, TLR was
erformed, which can increase the revascularization rates
n both groups. This routine follow-up angiography might
ontribute to the early detection of restenosis before theM. Nakamura et al.
ccurrence of severe cardiac events because restenosis may
e not always a benign event [36]. We believe that the
outine use of these medications, careful procedure dur-
ng PCI, and routine follow-up angiography might inﬂuence
he prognosis more powerfully than statin treatment in
erms of cardiovascular events and TLR, at least in the
hort-term. Although the pleiotropic effects of statins could
ontribute to reduced mortality, the reasons for the discrep-
ncy between mortality and morbidity in our study are not
ully explained and further studies to investigate the mech-
nism of early statin initiation to prevent fatal events are
equired.
tudy limitations
here are several limitations in the present study. First, the
tudy was a single center cohort and the event rates were
nfrequent, therefore the present study might be under-
owered to detect signiﬁcant differences in cardiovascular
vents. Then, although our ﬁndings were obtained by adjust-
ng confounding covariates and also assessing prognosis in
prespeciﬁed subgroup, our cohort study cannot adjust
or all confounders and thus, cannot replace a random-
zed controlled trial. Furthermore, we classiﬁed patients
ith statins into one group regardless of types and doses
f statins. Accordingly, it is possible that this classiﬁcation
ight inﬂuence the present ﬁndings. Finally, information
n medications and LDL-C and HDL-C values during follow-
p was not assessed, and some patients in the non-statin
roup might have subsequently started to take statins, while
thers in the statin group might have ceased the treat-
ent after the ﬁrst 3 months. However, this misclassiﬁcation
ias would have led to underestimate the present ﬁndings.
espite these limitations, we believe that our ﬁndings will
rovide valuable information about the future treatment for
atients with CAD in Japan, since the target population is
epresentative of patients seen in daily clinical practice and
he doses of statins in this study were consistent with those
sed in real-world clinical settings.
onclusions
he present study revealed that early initiated statin treat-
ent after the diagnosis of CAD can produce a beneﬁcial risk
eduction in mortality in Japanese patients with CAD.
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